镭-223联合卡博替尼治疗伴骨转移的肾细胞癌:II期随机试验RADICAL
RADICAL是一项II期随机试验,评估卡博替尼联合或不联合镭-223在伴骨转移的转移性肾细胞癌(mRCC)患者中的疗效。因预设中期无效性分析显示分层风险比(sHR)>1.0,试验提前终止,最终纳入98例患者。结果显示,联合镭-223未改善无骨骼相关事件生存期(SSE-FS),中位SSE-FS为16.7个月 vs 17.6个月(sHR=1.46,90%CI 0.86-2.51),且安全性可控。
要点
- 联合镭-223未改善SSE-FS,中位SSE-FS为16.7个月 vs 17.6个月(sHR=1.46)。
- 因无效性分析跨过边界,试验提前终止,最终分析98例患者。
- 联合组与单药组≥3级不良事件发生率相似(69.6% vs 75.5%)。
核心结论
- 在卡博替尼基础上加用镭-223未能改善伴骨转移mRCC患者的SSE-FS。
- 联合方案的安全性特征可控,与单药组相似。
研究设计与样本
- II期随机试验,纳入伴骨转移的mRCC患者(任何组织学类型),1:1随机分配至卡博替尼联合镭-223组或卡博替尼单药组。
- 按骨吸收靶向治疗(OTT)、既往治疗、阿片类药物使用和IMDC风险分层。
- 计划入组124例可评估患者,预设50%SSE-FS事件时进行中期无效性分析,若分层风险比(sHR)>1.0则终止试验。
- 最终分析纳入98例患者,中位年龄63岁,82.7%为透明细胞组织学,79.6%使用OTT。
主要发现
- 中位随访13.1个月,联合组与单药组的中位SSE-FS分别为16.7个月和17.6个月(sHR=1.46,90%CI 0.86-2.51)。
- 中位总生存期(OS)分别为28.3个月和19.7个月(sHR=1.40,95%CI 0.70-2.79)。
- ≥3级不良事件发生率分别为69.6%和75.5%。
临床怎么用
- 对于伴骨转移的mRCC患者,不推荐在卡博替尼基础上常规加用镭-223以改善SSE-FS。
- 联合方案的安全性可控,但未显示生存获益。
局限性
- 试验因无效性分析提前终止,最终样本量(98例)小于计划样本量(124例)。
- 中位随访时间较短(13.1个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS: This phase II trial enrolled patients with mRCC of any histology with ≥1 BM. Patients were randomly assigned 1:1 to cabozantinib ± radium-223, stratified by osteoclast-targeted therapy (OTT), prior therapy, opioid use, and International mRCC Database Consortium (IMDC) risk. The primary end point was SSE-free survival (SSE-FS). Secondary end points included safety, objective response rate (ORR), progression-free survival, and overall survival (OS). A target of 124 evaluable patients was planned, with a prespecified interim futility analysis at 50% of expected SSE-FS events; the trial would stop if the stratified hazard ratio (sHR) > 1.0. RESULTS: The prespecified interim futility analysis was conducted after 90 patients were enrolled and crossed the futility boundary, leading to closure at 98 patients. The final analysis included all 98 patients. Median age was 63 years, 82.7% had clear cell histology, and 79.6% were using an OTT. IMDC risk was favorable (18.4%), intermediate (67.3%), and poor (14.3%). Median follow-up was 13.1 months. Median SSE-FS for cabozantinib with radium-223 versus cabozantinib was 16.7 versus 17.6 months (sHR, 1.46 [90% CI, 0.86 to 2.51]). Median OS was 28.3 versus 19.7 months (sHR, 1.40 [95% CI, 0.70 to 2.79]). ORR was 19.4% versus 25.0% (P = .78). Grade ≥3 adverse events were similar across arms (69.6% v 75.5%). CONCLUSION: Radium-223 did not improve SSE-FS when added to cabozantinib. The combination demonstrated a manageable safety profile.
引用
- McKay RR, Ballman KV, Atherton PJ, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026. PMID: 42507969. doi:10.1200/JCO-26-01135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。